- Home
- BON vs ALLR Comparison
BON vs ALLR Comparison
Compare BON & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BON
- ALLR
- Stock Information
- Founded
- BON 2006
- ALLR 2004
- Country
- BON China
- ALLR United States
- Employees
- BON N/A
- ALLR N/A
- Industry
- BON Medicinal Chemicals and Botanical Products
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- BON Health Care
- ALLR Health Care
- Exchange
- BON Nasdaq
- ALLR Nasdaq
- Market Cap
- BON 6.6M
- ALLR 6.0M
- IPO Year
- BON 2021
- ALLR N/A
- Fundamental
- Price
- BON $1.12
- ALLR $0.95
- Analyst Decision
- BON
- ALLR
- Analyst Count
- BON 0
- ALLR 0
- Target Price
- BON N/A
- ALLR N/A
- AVG Volume (30 Days)
- BON 23.4K
- ALLR 2.3M
- Earning Date
- BON 02-28-2025
- ALLR 03-07-2025
- Dividend Yield
- BON N/A
- ALLR N/A
- EPS Growth
- BON N/A
- ALLR N/A
- EPS
- BON 0.17
- ALLR N/A
- Revenue
- BON $23,844,556.00
- ALLR N/A
- Revenue This Year
- BON $223.38
- ALLR N/A
- Revenue Next Year
- BON $18.82
- ALLR N/A
- P/E Ratio
- BON $6.42
- ALLR N/A
- Revenue Growth
- BON N/A
- ALLR N/A
- 52 Week Low
- BON $1.07
- ALLR $0.90
- 52 Week High
- BON $5.31
- ALLR $264.00
- Technical
- Relative Strength Index (RSI)
- BON 33.73
- ALLR 40.42
- Support Level
- BON $1.07
- ALLR $0.91
- Resistance Level
- BON $1.36
- ALLR $1.03
- Average True Range (ATR)
- BON 0.09
- ALLR 0.09
- MACD
- BON -0.01
- ALLR -0.02
- Stochastic Oscillator
- BON 18.28
- ALLR 13.88
About BON Bon Natural Life Limited
Bon Natural Life Ltd is engaged in the manufacturing of personal care ingredients, such as plants extracted fragrance compounds to perfume and fragrance manufacturers, natural health supplements such as powder drinks and bioactive food ingredient products mostly used as food additives and nutritional supplements. The company has its geographic presence in PRC and in Overseas. The company derives maximum revenue from perfumes and fragrance products.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.